Exploring the Landscape of Injury and Repair in the Human Oesophagus
Launched by THE WELLCOME SANGER INSTITUTE · Feb 5, 2025
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Tissue injury activates a number of cellular responses to initiate wound healing, resulting in the formation of new tissue within a short span of time and in a controlled fashion. In contrast, cancer results when a tissue mass forms in an unregulated process. Understanding the molecular mechanisms behind appropriate wound healing enables us to delineate how this process goes askew in the context of cancer. The goal is to delineate the mechanisms defining appropriate oesophageal injury and repair, and to use this information to understand how these rules are dysregulated and result in cancer...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and Female patients 18 years old and over who are having elective upper gastro-intestinal surgery where a leak is a recognised complication (but has not occurred)
- • Male and Female patients 18 years and over who present acutely with an upper gastro-intestinal leak.
- Exclusion Criteria:
- • patients who do not have a good understanding of the English Language
About The Wellcome Sanger Institute
The Wellcome Sanger Institute is a world-renowned genomics research center based in the UK, dedicated to advancing our understanding of human health and disease through cutting-edge genomic science. As a prominent sponsor of clinical trials, the institute leverages its expertise in genetics, bioinformatics, and large-scale data analysis to explore innovative therapeutic approaches and facilitate the translation of research findings into clinical applications. Committed to collaboration and excellence, the Wellcome Sanger Institute plays a pivotal role in the global biomedical research community, driving forward discoveries that have the potential to improve patient outcomes and transform healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, , United Kingdom
Patients applied
Trial Officials
AYESHA NOORANI, PhD MRCS
Principal Investigator
Genome Research Limited operating as The Wellcome Sanger Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported